![](https://ml.globenewswire.com/media/8e85b83b-047f-4f99-9c51-1aa232ffe9bb/small/aimlogo-jpg.jpg)
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and ...
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s antiviral …